Daiichi Sankyo (OTCMKTS:DSNKY) Shares Gap Up – Here’s Why

Daiichi Sankyo Co., Ltd. – Sponsored ADR (OTCMKTS:DSNKY) shares gapped up prior to trading on Friday . The stock had previously closed at $16.59, but opened at $17.2450. Daiichi Sankyo shares last traded at $17.27, with a volume of 1,553 shares trading hands.

Analyst Upgrades and Downgrades

Separately, Zacks Research upgraded Daiichi Sankyo from a “strong sell” rating to a “hold” rating in a research note on Tuesday, May 5th. One research analyst has rated the stock with a Hold rating, Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold”.

Daiichi Sankyo Price Performance

The company has a debt-to-equity ratio of 0.18, a quick ratio of 1.64 and a current ratio of 2.42. The company has a 50-day moving average of $16.36 and a 200-day moving average of $18.05. The stock has a market capitalization of $32.08 billion, a price-to-earnings ratio of 18.32, a P/E/G ratio of 2.88 and a beta of -0.17.

Daiichi Sankyo (OTCMKTS:DSNKY) last announced its earnings results on Monday, May 11th. The company reported $0.15 EPS for the quarter, missing analysts’ consensus estimates of $0.33 by ($0.18). The company had revenue of $3.76 billion for the quarter, compared to analyst estimates of $3.74 billion. Daiichi Sankyo had a net margin of 12.32% and a return on equity of 15.75%. Daiichi Sankyo has set its FY 2026 guidance at 0.910-0.910 EPS. As a group, equities research analysts expect that Daiichi Sankyo Co., Ltd. – Sponsored ADR will post 0.96 earnings per share for the current fiscal year.

About Daiichi Sankyo

Daiichi Sankyo Co, Ltd. is a global, research-driven pharmaceutical company headquartered in Tokyo, Japan. The company was formed through the merger of Daiichi Pharmaceutical and Sankyo in 2005 and focuses on the discovery, development, manufacturing and commercialization of prescription medicines. Its therapeutic priorities include oncology and cardiovascular disease, and it pursues a mix of small molecules, biologics and antibody‑drug conjugates in its development programs.

Daiichi Sankyo is known for building a development portfolio through both internal research and collaborative partnerships.